Table 1. Characteristics of BC patients.
| Variable | Total | Frequency (%) | |
|---|---|---|---|
| Diabetes mellitus | 11 | 8.1 | |
| Arterial hypertension | 35 | 25.7 | |
| Dyslipidemia | 37 | 27.2 | |
| Cardiac pathology | 4 | 2.9 | |
| Hypothyroidism | 10 | 7.4 | |
| Menopause state | |||
| Premenopausal | 29 | 21.3 | |
| Perimenopausal | 20 | 14.7 | |
| Postmenopausal | 85 | 62.5 | |
| Tumor molecular classification | |||
| Luminal A | 40 | 29.4 | |
| Luminal B | 50 | 36.8 | |
| Her2 positive | 27 | 19.9 | |
| Triple negative | 17 | 12.5 | |
| Ki67 antigen in tumor biopsy | |||
| <15 | 48 | 35.3 | |
| 15–50 | 62 | 45.6 | |
| >50 | 19 | 14.0 | |
| HER2 receptor in tumor biopsy | |||
| negative | 107 | 78.7 | |
| positive | 26 | 19.1 | |
| Estrogen receptors | |||
| negative | 22 | 16.2 | |
| positive | 113 | 83.1 | |
| Progesterone receptors | |||
| negative | 46 | 33.8 | |
| positive | 89 | 65.4 | |
| Chemotherapy | 75 | 55.1 | |
| Hormone therapy | 107 | 78.7 | |
| Targeted therapy | 24 | 17.6 | |
| BC location | |||
| Right | 66 | 48.5 | |
| Left | 68 | 50.0 | |
| Bilateral | 2 | 1.5 | |
BC, breast cancer; HER2, human epidermal growth factor receptor 2.